AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung‐Yun Lee, Lingying Wu, Jeong‐Won Lee et al.|Gynecologic Oncology|2025Cited by 7
[Abstract] Feeding eggs improves plasma markers of choline statusYun Shih, Bonny Burns‐Whitmore, W. Wang et al.|The FASEB Journal|2011Cited by 0